Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers

Interindividual variability in drug pharmacokinetics and susceptibility to drug-drug interactions remain major barriers in precision dosing, particularly for narrow therapeutic index drugs. While genetic factors contribute, much variability arises from dynamic influences such as physiology, disease, age, diet, microbiome, and concomitant medications. Conventional approaches provide limited retrospective insight. Emerging phenotypic biomarkers offer a proactive, mechanism-based strategy to quantify variability, improve exposure prediction, assess drug interaction risk, and individualize dosing beyond pharmacogenomics.